Efficient-Pro Medium and Feed 1 enable rapid and seamless upstream process development and scale-up for CHO-K1 cells Bioproduction White paper | Efficient-Pro Medium and Efficient-Pro Feed 1 Introduction Protein-based biotherapeutics, particularly monoclonal antibodies (mAbs), are considered the most successful and fastest-growing pharmaceuticals, with a projected 15% annual growth rate expected over the next decade [1]. Some of the anticipated growth will be driven by the rising global demand for improved therapies to replace less effective treatments, as well as new treatments to address unmet needs. Effectively meeting these demands will require accelerated product development strategies and increased scale-up production capabilities [2,3]. Manufacturers of biotherapeutics hav

Join for free to read